The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer

Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089

Carlos M. Perez-Stable, Adan Farinas, Guy A. Howard, Bernard A. Roos, Carlos M. Perez-Stable, Guy A. Howard, Bernard A. Roos, Guy A. Howard, Bernard A. Roos, Carlos M. Perez-Stable, Guy A. Howard, Bernard A. Roos, Gary Schwartz, Milton Finegold, Lise Binderup

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Transgenic mouse models of prostate cancer provide unique opportunities to understand the molecular events in prostate carcinogenesis and for the preclinical testing of new therapies. We studied the GγT-15 transgenic mouse line, which contains the human fetal globin promoter linked to SV40 T antigen (Tag) and which develops androgen-independent prostate cancer. Using the immunohistochemistry of normal mouse prostates before tumor formation, we showed that the target cells of carcinogenesis in GγT-15 mice are located in the basal epithelial layer. We tested the efficacy of the 1,25(OH)2D3 analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. Compared with treatment with placebo, treatment with EB 1089 at three different time points before the onset of prostate tumors in mice did not prevent or delay tumor onset. However, EB 1089 significantly inhibited prostate tumor growth. At the highest dose, EB1089 inhibited prostate tumor growth by 60% (P = 0.0003) and the growth in the number of metastases, although this dose also caused significant hypercalcemia and weight loss. We conducted several in vitro experiments to explore why EB 1089 did not prevent the occurrence of the primary tumors. EB1089 significantly inhibited the growth of a Tag-expressing human prostate epithelial cell line, BPH-1, and an androgen-insensitive subline of LNCaP cells [which was not inhibited by 1,25(OH)2D3]. Thus, neither Tag expression nor androgen insensitivity explain the absence of chemopreventive effect. Conversely, neither 1,25(OH)2D3 nor EB 1089 inhibited the growth of the normal rat prostate basal epithelial cell line NRP-152. It is likely that EB 1089 was not effective in delaying the growth of the primary tumor in GγT-15 transgenic mice because the target cells of carcinogenesis in these mice are located in the basal epithelial layer. We conclude that GγT-15 transgenic mice are a useful model for testing vitamin D-based therapies in androgen-insensitive prostate cancer but are not suitable for studies of vitamin D-hased chemoprevention. The superiority of EB 1089 over 1,25(OH)2D3 in the growth suppression of androgeninsensitive prostate cancer cells supports the use of EB 1089 in androgen-insensitive prostate cancer.

Original languageEnglish (US)
Pages (from-to)555-563
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number6
StatePublished - Jan 1 2002

Fingerprint

Vitamin D
Transgenic Mice
Androgens
Prostatic Neoplasms
Carcinogenesis
Prostate
Growth
Neoplasms
Viral Tumor Antigens
Epithelial Cells
seocalcitol
Polyomavirus Transforming Antigens
Cell Line
Globins
Chemoprevention
Hypercalcemia
Therapeutics
Weight Loss
Immunohistochemistry
Placebos

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Perez-Stable, C. M., Farinas, A., Howard, G. A., Roos, B. A., Perez-Stable, C. M., Howard, G. A., ... Binderup, L. (2002). The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. Cancer Epidemiology Biomarkers and Prevention, 11(6), 555-563.

The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer : Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. / Perez-Stable, Carlos M.; Farinas, Adan; Howard, Guy A.; Roos, Bernard A.; Perez-Stable, Carlos M.; Howard, Guy A.; Roos, Bernard A.; Howard, Guy A.; Roos, Bernard A.; Perez-Stable, Carlos M.; Howard, Guy A.; Roos, Bernard A.; Schwartz, Gary; Finegold, Milton; Binderup, Lise.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 6, 01.01.2002, p. 555-563.

Research output: Contribution to journalArticle

Perez-Stable, CM, Farinas, A, Howard, GA, Roos, BA, Perez-Stable, CM, Howard, GA, Roos, BA, Howard, GA, Roos, BA, Perez-Stable, CM, Howard, GA, Roos, BA, Schwartz, G, Finegold, M & Binderup, L 2002, 'The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089', Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 6, pp. 555-563.
Perez-Stable, Carlos M. ; Farinas, Adan ; Howard, Guy A. ; Roos, Bernard A. ; Perez-Stable, Carlos M. ; Howard, Guy A. ; Roos, Bernard A. ; Howard, Guy A. ; Roos, Bernard A. ; Perez-Stable, Carlos M. ; Howard, Guy A. ; Roos, Bernard A. ; Schwartz, Gary ; Finegold, Milton ; Binderup, Lise. / The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer : Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089. In: Cancer Epidemiology Biomarkers and Prevention. 2002 ; Vol. 11, No. 6. pp. 555-563.
@article{e3246ceb88c34783b841b99498520303,
title = "The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer: Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089",
abstract = "Transgenic mouse models of prostate cancer provide unique opportunities to understand the molecular events in prostate carcinogenesis and for the preclinical testing of new therapies. We studied the GγT-15 transgenic mouse line, which contains the human fetal globin promoter linked to SV40 T antigen (Tag) and which develops androgen-independent prostate cancer. Using the immunohistochemistry of normal mouse prostates before tumor formation, we showed that the target cells of carcinogenesis in GγT-15 mice are located in the basal epithelial layer. We tested the efficacy of the 1,25(OH)2D3 analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. Compared with treatment with placebo, treatment with EB 1089 at three different time points before the onset of prostate tumors in mice did not prevent or delay tumor onset. However, EB 1089 significantly inhibited prostate tumor growth. At the highest dose, EB1089 inhibited prostate tumor growth by 60{\%} (P = 0.0003) and the growth in the number of metastases, although this dose also caused significant hypercalcemia and weight loss. We conducted several in vitro experiments to explore why EB 1089 did not prevent the occurrence of the primary tumors. EB1089 significantly inhibited the growth of a Tag-expressing human prostate epithelial cell line, BPH-1, and an androgen-insensitive subline of LNCaP cells [which was not inhibited by 1,25(OH)2D3]. Thus, neither Tag expression nor androgen insensitivity explain the absence of chemopreventive effect. Conversely, neither 1,25(OH)2D3 nor EB 1089 inhibited the growth of the normal rat prostate basal epithelial cell line NRP-152. It is likely that EB 1089 was not effective in delaying the growth of the primary tumor in GγT-15 transgenic mice because the target cells of carcinogenesis in these mice are located in the basal epithelial layer. We conclude that GγT-15 transgenic mice are a useful model for testing vitamin D-based therapies in androgen-insensitive prostate cancer but are not suitable for studies of vitamin D-hased chemoprevention. The superiority of EB 1089 over 1,25(OH)2D3 in the growth suppression of androgeninsensitive prostate cancer cells supports the use of EB 1089 in androgen-insensitive prostate cancer.",
author = "Perez-Stable, {Carlos M.} and Adan Farinas and Howard, {Guy A.} and Roos, {Bernard A.} and Perez-Stable, {Carlos M.} and Howard, {Guy A.} and Roos, {Bernard A.} and Howard, {Guy A.} and Roos, {Bernard A.} and Perez-Stable, {Carlos M.} and Howard, {Guy A.} and Roos, {Bernard A.} and Gary Schwartz and Milton Finegold and Lise Binderup",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "555--563",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - The Gγ/T-15 transgenic mouse model of androgen-independent prostate cancer

T2 - Target cells of carcinogenesis and the effect of the vitamin D analogue EB 1089

AU - Perez-Stable, Carlos M.

AU - Farinas, Adan

AU - Howard, Guy A.

AU - Roos, Bernard A.

AU - Perez-Stable, Carlos M.

AU - Howard, Guy A.

AU - Roos, Bernard A.

AU - Howard, Guy A.

AU - Roos, Bernard A.

AU - Perez-Stable, Carlos M.

AU - Howard, Guy A.

AU - Roos, Bernard A.

AU - Schwartz, Gary

AU - Finegold, Milton

AU - Binderup, Lise

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Transgenic mouse models of prostate cancer provide unique opportunities to understand the molecular events in prostate carcinogenesis and for the preclinical testing of new therapies. We studied the GγT-15 transgenic mouse line, which contains the human fetal globin promoter linked to SV40 T antigen (Tag) and which develops androgen-independent prostate cancer. Using the immunohistochemistry of normal mouse prostates before tumor formation, we showed that the target cells of carcinogenesis in GγT-15 mice are located in the basal epithelial layer. We tested the efficacy of the 1,25(OH)2D3 analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. Compared with treatment with placebo, treatment with EB 1089 at three different time points before the onset of prostate tumors in mice did not prevent or delay tumor onset. However, EB 1089 significantly inhibited prostate tumor growth. At the highest dose, EB1089 inhibited prostate tumor growth by 60% (P = 0.0003) and the growth in the number of metastases, although this dose also caused significant hypercalcemia and weight loss. We conducted several in vitro experiments to explore why EB 1089 did not prevent the occurrence of the primary tumors. EB1089 significantly inhibited the growth of a Tag-expressing human prostate epithelial cell line, BPH-1, and an androgen-insensitive subline of LNCaP cells [which was not inhibited by 1,25(OH)2D3]. Thus, neither Tag expression nor androgen insensitivity explain the absence of chemopreventive effect. Conversely, neither 1,25(OH)2D3 nor EB 1089 inhibited the growth of the normal rat prostate basal epithelial cell line NRP-152. It is likely that EB 1089 was not effective in delaying the growth of the primary tumor in GγT-15 transgenic mice because the target cells of carcinogenesis in these mice are located in the basal epithelial layer. We conclude that GγT-15 transgenic mice are a useful model for testing vitamin D-based therapies in androgen-insensitive prostate cancer but are not suitable for studies of vitamin D-hased chemoprevention. The superiority of EB 1089 over 1,25(OH)2D3 in the growth suppression of androgeninsensitive prostate cancer cells supports the use of EB 1089 in androgen-insensitive prostate cancer.

AB - Transgenic mouse models of prostate cancer provide unique opportunities to understand the molecular events in prostate carcinogenesis and for the preclinical testing of new therapies. We studied the GγT-15 transgenic mouse line, which contains the human fetal globin promoter linked to SV40 T antigen (Tag) and which develops androgen-independent prostate cancer. Using the immunohistochemistry of normal mouse prostates before tumor formation, we showed that the target cells of carcinogenesis in GγT-15 mice are located in the basal epithelial layer. We tested the efficacy of the 1,25(OH)2D3 analogue, EB 1089, to chemoprevent prostate cancer in these transgenic mice. Compared with treatment with placebo, treatment with EB 1089 at three different time points before the onset of prostate tumors in mice did not prevent or delay tumor onset. However, EB 1089 significantly inhibited prostate tumor growth. At the highest dose, EB1089 inhibited prostate tumor growth by 60% (P = 0.0003) and the growth in the number of metastases, although this dose also caused significant hypercalcemia and weight loss. We conducted several in vitro experiments to explore why EB 1089 did not prevent the occurrence of the primary tumors. EB1089 significantly inhibited the growth of a Tag-expressing human prostate epithelial cell line, BPH-1, and an androgen-insensitive subline of LNCaP cells [which was not inhibited by 1,25(OH)2D3]. Thus, neither Tag expression nor androgen insensitivity explain the absence of chemopreventive effect. Conversely, neither 1,25(OH)2D3 nor EB 1089 inhibited the growth of the normal rat prostate basal epithelial cell line NRP-152. It is likely that EB 1089 was not effective in delaying the growth of the primary tumor in GγT-15 transgenic mice because the target cells of carcinogenesis in these mice are located in the basal epithelial layer. We conclude that GγT-15 transgenic mice are a useful model for testing vitamin D-based therapies in androgen-insensitive prostate cancer but are not suitable for studies of vitamin D-hased chemoprevention. The superiority of EB 1089 over 1,25(OH)2D3 in the growth suppression of androgeninsensitive prostate cancer cells supports the use of EB 1089 in androgen-insensitive prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0036277685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036277685&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 555

EP - 563

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -